...
mrus-img

Merus BV, Common Stock

MRUS

NMQ

$41.85

-$0.24

(-0.57%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.88B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
735.81K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.13
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$27.11 L
$61.61 H
$41.85

About Merus BV, Common Stock

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMRUSSectorS&P500
1-Week Return-2.29%-2.12%-3%
1-Month Return-2.52%-3.42%-0.73%
3-Month Return-15.74%-11.13%2.87%
6-Month Return-22.41%-5.74%7.17%
1-Year Return61.71%3.97%25.31%
3-Year Return40.11%1.05%28.38%
5-Year Return146.18%34.37%81.89%
10-Year Return316.83%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue31.13M29.94M49.11M41.59M43.95M[{"date":"2019-12-31","value":63.4,"profit":true},{"date":"2020-12-31","value":60.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.68,"profit":true},{"date":"2023-12-31","value":89.49,"profit":true}]
Cost of Revenue49.64M57.33M86.27M11.98M127.41M[{"date":"2019-12-31","value":38.96,"profit":true},{"date":"2020-12-31","value":45,"profit":true},{"date":"2021-12-31","value":67.71,"profit":true},{"date":"2022-12-31","value":9.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(18.51M)(27.39M)(37.16M)29.60M43.95M[{"date":"2019-12-31","value":-42.11,"profit":false},{"date":"2020-12-31","value":-62.33,"profit":false},{"date":"2021-12-31","value":-84.56,"profit":false},{"date":"2022-12-31","value":67.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(59.44%)(91.48%)(75.67%)71.19%100.00%[{"date":"2019-12-31","value":-59.44,"profit":false},{"date":"2020-12-31","value":-91.48,"profit":false},{"date":"2021-12-31","value":-75.67,"profit":false},{"date":"2022-12-31","value":71.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses89.79M105.82M139.08M201.62M200.49M[{"date":"2019-12-31","value":44.53,"profit":true},{"date":"2020-12-31","value":52.48,"profit":true},{"date":"2021-12-31","value":68.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.44,"profit":true}]
Operating Income(58.66M)(75.88M)(89.98M)(160.04M)(156.55M)[{"date":"2019-12-31","value":-5865700000,"profit":false},{"date":"2020-12-31","value":-7587800000,"profit":false},{"date":"2021-12-31","value":-8997600000,"profit":false},{"date":"2022-12-31","value":-16003800000,"profit":false},{"date":"2023-12-31","value":-15654700000,"profit":false}]
Total Non-Operating Income/Expense5.59M(22.60M)12.35M21.95M15.55M[{"date":"2019-12-31","value":25.47,"profit":true},{"date":"2020-12-31","value":-102.96,"profit":false},{"date":"2021-12-31","value":56.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.84,"profit":true}]
Pre-Tax Income(54.96M)(85.01M)(66.58M)(130.24M)(151.75M)[{"date":"2019-12-31","value":-5495700000,"profit":false},{"date":"2020-12-31","value":-8501000000,"profit":false},{"date":"2021-12-31","value":-6657700000,"profit":false},{"date":"2022-12-31","value":-13023500000,"profit":false},{"date":"2023-12-31","value":-15174700000,"profit":false}]
Income Taxes194.00K503.00K239.00K959.00K3.19M[{"date":"2019-12-31","value":6.08,"profit":true},{"date":"2020-12-31","value":15.76,"profit":true},{"date":"2021-12-31","value":7.49,"profit":true},{"date":"2022-12-31","value":30.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(55.15M)(85.51M)(66.82M)(131.19M)(154.94M)[{"date":"2019-12-31","value":-5515100000,"profit":false},{"date":"2020-12-31","value":-8551300000,"profit":false},{"date":"2021-12-31","value":-6681600000,"profit":false},{"date":"2022-12-31","value":-13119400000,"profit":false},{"date":"2023-12-31","value":-15493900000,"profit":false}]
Income From Continuous Operations(55.15M)(85.51M)(66.82M)(131.19M)(176.76M)[{"date":"2019-12-31","value":-5515100000,"profit":false},{"date":"2020-12-31","value":-8551300000,"profit":false},{"date":"2021-12-31","value":-6681600000,"profit":false},{"date":"2022-12-31","value":-13119400000,"profit":false},{"date":"2023-12-31","value":-17675800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(55.15M)(85.51M)(66.82M)(131.19M)(154.94M)[{"date":"2019-12-31","value":-5515100000,"profit":false},{"date":"2020-12-31","value":-8551300000,"profit":false},{"date":"2021-12-31","value":-6681600000,"profit":false},{"date":"2022-12-31","value":-13119400000,"profit":false},{"date":"2023-12-31","value":-15493900000,"profit":false}]
EPS (Diluted)(2.04)(2.86)(1.72)(2.90)(2.99)[{"date":"2019-12-31","value":-204,"profit":false},{"date":"2020-12-31","value":-286,"profit":false},{"date":"2021-12-31","value":-172,"profit":false},{"date":"2022-12-31","value":-290,"profit":false},{"date":"2023-12-31","value":-299,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MRUS
Cash Ratio 7.90
Current Ratio 8.32

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MRUS
ROA (LTM) -21.60%
ROE (LTM) -44.60%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MRUS
Debt Ratio Lower is generally better. Negative is bad. 0.17
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.83

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MRUS
Trailing PE NM
Forward PE NM
P/S (TTM) 80.20
P/B 4.10
Price/FCF NM
EV/R 62.91
EV/Ebitda NM
PEG NM

FAQs

What is Merus BV share price today?

Merus BV (MRUS) share price today is $41.85

Can Indians buy Merus BV shares?

Yes, Indians can buy shares of Merus BV (MRUS) on Vested. To buy Merus BV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MRUS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Merus BV be purchased?

Yes, you can purchase fractional shares of Merus BV (MRUS) via the Vested app. You can start investing in Merus BV (MRUS) with a minimum investment of $1.

How to invest in Merus BV shares from India?

You can invest in shares of Merus BV (MRUS) via Vested in three simple steps:

  • Click on Sign Up or Invest in MRUS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Merus BV shares
What is Merus BV 52-week high and low stock price?

The 52-week high price of Merus BV (MRUS) is $61.61. The 52-week low price of Merus BV (MRUS) is $27.11.

What is Merus BV price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Merus BV (MRUS) is

What is Merus BV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Merus BV (MRUS) is 4.10

What is Merus BV dividend yield?

The dividend yield of Merus BV (MRUS) is 0.00%

What is the Market Cap of Merus BV?

The market capitalization of Merus BV (MRUS) is $2.88B

What is Merus BV’s stock symbol?

The stock symbol (or ticker) of Merus BV is MRUS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top